Addition of Severe Combined Immunodeficiency as a Contraindication for Administration of Rotavirus Vaccine
In response to reported cases of vaccine-acquired rotavirus infection in infants with severe combined immunodeficiency (SCID) following rotavirus vaccine administration, both Merck & Co. and GlaxoSmithKline Biologicals have revised the prescribing information and patient labeling for their respective rotavirus vaccine products with approval from the US Food and Drug Administration. The US Centers for Disease Control and Prevention (CDC) is now updating the list of contraindications for rotavirus vaccine for infants diagnosed with SCID. This report was published in the CDC's Morbidity and Mortality Weekly Report.
Author(s): US Centers for Disease Control and Prevention
Visit web page (English)
(Located at www.cdc.gov)